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The objective of this investigation was to develop a novel oral edible gel dosage form for nebivolol 
hydrochloride, with suitable rheological characteristics that can provide a means of administering the 
drug to dysphagic and geriatric patients. Edible gels were prepared using low acetylated gellan gum and 
sodium citrate in different concentrations. The effect of concentration of the solution on gelation time, 
viscosity, and drug release was studied. Optimized formulation had “spoon thick” consistency that is 
considered suitable for dysphagic patients as suggested by National Dysphagia Diet Task Force. The 
optimized formulation containing gellan gum (0.4 % w/v) and sodium citrate (0.3 % w/v) showed more 
than 95% drug release in 20 minutes. This formulation also showed significantly better pharmacokinetic 
profile when compared to marketed conventional tablets in New Zealand white rabbits (n = 3). Optimized 
formulation was found stable for 6 months when stored at 25 °C ± 0.2 °C/60 ± 5% RH. From this study, 
it can be concluded that the novel edible gel dosage form containing nebivolol hydrochloride may prove 
to be more efficacious in the treatment of hypertension in dysphagic patients.
Uniterms: Edible gel/pharmaceutics. Nebivolol HCl/delivery. Dysphagia/drugs administration.
O objetivo deste trabalho foi desenvolver um gel comestível para veiculação de cloridrato de nebivolol, 
com características reológicas adequadas, que podem fornecer meio de administrar o fármaco em casos 
de disfagia orofaríngea e pacientes geriátricos. Géis comestíveis foram preparados utilizando goma gelana 
de baixa acetilação e citrato de sódio, em diferentes concentrações. Estudou-se o efeito da concentração 
da solução no tempo de gelificação, a viscosidade e a liberação do fármaco. A formulação otimizada 
apresentava consistência de pudim, o que é considerado adequado para pacientes disfágicos como sugerido 
pela National Dysphagia Diet Task Force. A formulação otimizada contendo 0,4% (m/v) de goma gelana 
e 0,3% (m/v) de citrato de sódio mostrou que mais de 95% de fármaco foi liberado em 20 minutos. Esta 
formulação também mostrou, significativamente, melhor perfil farmacocinético, quando comparado com 
os comprimidos convencionais comercializados administrados a coelhos brancos neozelandeses (n = 3). 
A formulação otimizada manteve-se estável durante 6 meses, armazenada a 25 oC ± 0,2 °C/60 ± 5%  
de UR. A partir deste estudo, conclui-se que a nova forma de gel comestível contendo cloridrato de 
nebivolol pode ser mais eficaz no tratamento de hipertensão em pacientes portadores de disfagia.
Unitermos: Gel comestível/farmacotécnica. Cloridrato de nebivolol/veiculação. Disfagia/administração 
de fármacos.
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INTRODUCTION
Oral administration of drugs is most preferred 
because of its ease of ingestion, no pain and improved 
patient compliance. However, dysphagic patients 
experience difficulty in swallowing with existing oral 
dosage forms such as tablets and capsules. Administration 
of oral liquids may result in choking in these patients 
(Dixit, Parthasarathi, Hosakote, 2011). Moreover, elderly 
patients cannot easily take tablets or capsules. The physical 
injury caused upon rubbing of the solid preparation against 
mucous membrane can discomfort the patient (Dixit, 
Parthasarathi, Hosakote, 2011). Crushing of enteric coated 
tablets or controlled release tablets is undesirable, as this 
may lead to loss of efficacy of the dosage form (Jackson 
et al., 2008). 
 Dysphagia is a biomechanical disorder considered 
as a clinical syndrome (PBM, 2006). It is defined as “an 
inability to swallow, or a sensation that solids or liquids 
do not pass easily from the mouth to the stomach” (PBM, 
2006). From many reported studies it has been estimated 
that over six million adults have dysphagia (PBM, 2006). 
It can occur in all age groups, but the prevalence increases 
with increase in age and in Parkinson’s disease (PBM, 
2006; Shirley, 2013). 
Nebivolol HCl (NEB) is a cardio selective third 
generation β-receptor blocking agent, used orally in the 
treatment of hypertension (Bystolic, 2007). After oral 
administration, it reaches peak plasma concentration 
within 0.5-2 h. Oral bioavailability of NEB is only 12 % 
in extensive metabolizers (majority of the population) as 
it undergoes extensive first pass hepatic metabolism due 
to cytochrome P450 2D6 (CYP2D6) enzymes. Half-life 
also varies extensively from 10.3 h to 31.9 h in extensive 
and poor metabolizers respectively. The recommended 
dose of NEB is 5 mg per day. Depending on the blood 
pressure (BP) of the patient, dose may be increased slowly 
at 2 weeks intervals to a maximum of up to 40 mg per day 
(Hilas, Danielle, 2009).
Hypertension is a common disease of the elderly. 
From the literature, we know that 60-80% of the elderly 
patient population (age above 60-65 years) suffer from 
hypertension (Malyszko et al., 2013). Further, there are 
several factors that cause dysphagia. Of these, senescence 
is a major factor. Many of these older patients who 
suffer from dysphagia also concomitantly suffer from 
hypertension. Therefore, there exists some white space 
for the development of edible dosage forms for elderly 
patients suffering from dysphagia coupled with other 
chronic diseases like hypertension. In this work, we used 
NEB as a model drug and it was selected owing to its high 
prescription volumes and poor oral bioavailability (~12% 
in humans). 
Thickened liquids play a vital role in reducing risk 
of aspiration for dysphagic patients. Previous studies 
have indicated the importance of viscosity as a bolus 
variable during the swallowing process (Bisch et al., 1994; 
Dantas et al., 1990). Dietary professionals work closely 
with the speech-language pathologists to determine the 
appropriate consistencies of fluid for each patient (Duke 
Medicine, 2007; Wexner Medical Center, 2013). In 2002, 
the American Dietetic Association established the National 
Dysphagia Diet (NDD) guidelines for thickened dietary 
supplements (Gary, Cathy, Catriona, 2003). To ensure 
safety during oral administration, patients with dysphagia 
require an appropriate oral dosage form or modification 
of the dosage form.
There is clearly a need for a suitable dosage form 
that can address the low bioavailability of NEB and also 
eases the administration of drugs to dysphagic patients. 
This study tries to address the same by formulating 
NEB into novel oral edible gel (OEG) dosage form. We 
formulated the OEG using gellan gum as polymer and 
assessed the in-vitro and in-vivo performance of the same. 
MATERIAL AND METHODS
Material
Nebivolol HCl was obtained as gift sample from 
Aurobindo Pharma, Hyderabad, India. Gellan gum was 
gift sample from Mylan laboratories Ltd, Hyderabad, 
India. PEG 400, citric acid, mannitol, methyl paraben, 
were purchased from ESSEL fine chem., Mumbai, India. 
Strawberry flavor was purchased from Robin chemicals, 
Mumbai. Sucralose was obtained from J.K. Suralose Inc. 
Ltd., Delhi. All other ingredients used were of analytical 
reagent grade. 
Methods
Formulation of oral edible gel
All ingredients were passed through ASTM sieve 
# 60 and accurately weighed. The details of the composition 
are shown in Table I. Gellan gum powder was dispersed in 
50 mL of distilled water maintained at 95 °C. The dispersion 
was stirred at same temperature for 20 min using a magnetic 
stirrer (Remi PMDC, Mumbai, India) to facilitate hydration 
of the gellan gum. The required amount of mannitol was 
added to the gellan gum solution with continuous stirring. 
NEB was then added to it under stirring. Citric acid, 
methylparaben were added and mixed. Sodium citrate 
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previously dissolved in 10 mL distilled water was added 
to the mixture. Strawberry flavor was added at last when 
temperature reached below 40 °C. Weight of the gel was 
adjusted finally to 100 g with distilled water. The mixture 
was allowed to cool to room temperature to form gel. The 
gels were prepared using five different concentrations of 
gellan gum (0.1, 0.2, 0.3, 0.4 and 0.5 % w/v), each with two 
different sodium citrate concentrations (0.3 and 0.5 % w/v) 
(Mohapatra, Parikh, Gohel, 2008).
Evaluation of oral edible gel
Oral edible gels were subjected to various evaluation 
parameters.
• Determination of gelation time
Gelation time was determined by placing the 
prepared gel in 20 mL flat bottomed cylindrical vial 
maintained at 25 ± 0.2 °C. The gelation time was 
considered as the time taken for the formulation to convert 
from “sol” state to “gel” state (Hanawa et al., 1995).
• Appearance and texture evaluation of the gel
Texture of the gel was evaluated in terms of 
stickiness and grittiness by mildly rubbing the gel between 
two fingers (Gohel et al., 2009). The gel formulations were 
visually inspected for transparency.
• pH of the edible gel
pH influences stability and taste of the final 
formulation. Hence, the pH of edible gel was measured 
using digital pH meter by checking the pH of a 10% w/v 
gel-dispersed in purified water at 25 ± 0.5 °C (Mohapatra, 
Parikh, Gohel, 2008; Dabhi et al., 2011). 
• Syneresis
Separation of water by contraction of the gel 
upon standing is known as syneresis. Syneresis is more 
pronounced in the gel where very low concentration 
of gelling agent is used. Prepared gels were kept under 
scrutiny for signs of syneresis in refrigerator (4-8 °C) for 
90 days (Mohapatra, Parikh, Gohel, 2008; Dabhi et al., 
2011; Gerentes et al., 2002).
• Fourier Transform Infrared Spectroscopy (FTIR) 
studies
FTIR studies were performed to find any possible 
drug-excipient interaction by KBr pellet method using 
Perkin-Elmer spectrophotometer, USA (Model-1615). For 
this study, physical mixtures of drug and excipient (1:1) 
were prepared and co-ground with KBr. The resultant 
mixture was subjected to FTIR studies. Scans were 
performed from 400-4000 cm-1 and an average of 40 scans 
were taken per sample.
• Differential scanning calorimeter (DSC) studies
Differential scanning calorimetry (DSC) was 
performed on pure NEB and optimized gel formulation. 
Calorimetric analysis was carried out using DSC 60 
(Shimadzu Corporation, Kyoto, Japan) instrument. Briefly, 
accurately weighted sample was taken in an aluminum 
pan and crimp sealed. In the DSC chamber, samples 
were allowed to equilibrate at 25 °C. Then, the samples 
were subjected to heating run over temperature range of 
25-300 °C at a heating rate of 5 °C/min. DSC curves were 
directly obtained from the software supplied with the 
instrument (Punna Rao et al., 2014).
TABLE I - Formulation of oral edible gel
Ingredients
Formulations
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10
Nebivolol (mg) 200 200 200 200 200 200 200 200 200 200
Gellan gum (%) 0.1 0.1 0.2 0.2 0.3 0.3 0.4 0.4 0.5 0.5
PEG 400 (%) 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Citric acid (%) 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05
Mannitol (%) 30 30 30 30 30 30 30 30 30 30
Sucralose (%) 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3
Sodium citrate (%) 0.3 0.5 0.3 0.5 0.3 0.5 0.3 0.5 0.3 0.5
Methyl paraben (%) 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Strawberry (%) 2 2 2 2 2 2 2 2 2 2
Water (% w/w) up to 100 100 100 100 100 100 100 100 100 100
PEG = Polyethylene glycol.
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• Viscosity and consistency
Gels were prepared according to the viscosity 
guidelines given by national dysphagia diet task force 
(Dixit, Parthasarathi, Hosakote, 2011). Viscosity of the 
all the batches of gels was measured using Brookfield 
DV-II+Pro viscometer using spindle number LV4 at the 
rotation of 50 rpm at room temperature. The viscosity 
measurements were made in triplicate using fresh samples 
each time (Mohapatra, Parikh, Gohel, 2008).
• Drug content assay
A known quantity of gel (5 g) was taken in a 30 mL 
volumetric flask containing solvent system methanol: 
water (80:20 % v/v). This was then shaken on a mechanical 
shaker for 1 h to get a homogeneous solution that was 
filtered (Whatman 0.45 micron PVDF syringe filter). The 
drug content was determined using HPLC after appropriate 
dilution (Sahoo, Giri, 2009). Experiment was performed in 
triplicate. The gels were considered to comply with the test 
if, not more than one of the values obtained was outside 
the limits of 85-115 % of the average value and none was 
outside the limits 75-125 % (USP, 2000). 
• In vitro drug release studies and release kinetics 
In vitro drug release from the gels were studied 
using USP XXIV dissolution apparatus II (Electrolab, 
Mumbai, India) employing a paddle stirrer at 100 rpm 
using 900 mL of pH 6.8 phosphate buffer at 37 ± 0.5 °C 
as a dissolution medium (Raju et al., 2011). 5 g of gel 
formulation was accurately weighed and placed at the 
bottom of the dissolution vessel. Aliquots (5 mL each) 
were withdrawn at specified time intervals (2, 4, 6, 8, 10, 
12, 14, 16, 18, 20, 25 and 30 min) and media replaced 
with equal volume each time. All the studies were 
done in triplicate (n = 3). The samples were analyzed 
for drug content using HPLC (Sahoo, Giri, 2009). The 
drug release profile was fitted into several mathematical 
models like zero order, first order kinetics, Higuchi and 
Peppas model to get an insight of release mechanism of 
the drug from the dosage form.
• Chromatographic conditions
The HPLC was used for determination of drug 
content assay and in-vitro drug release studies. The 
details of the study are as follows: Instrument: Shimadzu 
LC-10AT and LC-10AT VP series HPLC pumps; Mobile 
Phase: Methanol:Water (80:20, v/v); Column type: 
Hypersil ODS C18 (250 x 4.6 mm, 5 μm); Wavelength: 
282 nm; Flow rate: 1 mL/min; Detector type: SPD 10A 
VP UV-Visible absorbance detector. The linearity range 
was: 1 to 450 µg/mL; Limit of Detection was 100 ng/mL 
and the Limit of Quantification was 250 ng/mL (Sahoo, 
Giri, 2009).
• Stability studies
Optimized gel formulations were stored in high-
density polyethylene bottles at 25 °C ± 0.2 °C / 60 ± 5 % 
RH and 40 ± 2 °C / 75 ± 5 % RH in a stability chamber 
(Ostwald stability chamber JRIC-11) for 6 months and 
3 months respectively. Samples were withdrawn with 
30 days intervals up to 6 months and were evaluated for 
their physical appearance, pH, viscosity, assay and drug 
release (Dixit, Kulkarni, 2012).
• In vivo studies
The in vivo studies were performed in male New 
Zealand white rabbits (n = 6). Animal ethical committee 
clearance was taken before performing the experiment 
(CPCSEA/IAEC/EXP/25/50/2013/EXP-02). The rabbits 
were fasted overnight (12 h) before administration of the 
formulations. The animals were randomly divided into two 
groups (A and B) with three animals in each group. Group 
A rabbits were anaesthetized with intravenous injection of 
pentobarbital at a dose of 25 mg/kg (Setouhy, Malak, 2010). 
Then they were positioned on a table with the lower jaw 
supported in a horizontal position (Kishore et al., 2013). 
The gel formulation was carefully placed on the tongue of 
group ‘A’ rabbits. As a control, marketed tablet (Nebicard, 
Torrent Pharmaceuticals limited, India) was administered 
orally by dispersing it in 2 mL of water to group ‘B’ rabbits 
via oral gavage (Kishore et al., 2013). The dose of 10 mg/kg 
body weight was chosen for the study based on previously 
reported literature (Punna Rao et al., 2015). 
Blood samples (1 mL) for pharmacokinetic analysis 
were obtained by marginal ear vein puncture at different 
time intervals (0, 15, 30, 45, 60, 120, 240, 360, 480 min, 
12, 24 and 36 h) post dosing. Blood samples were collected 
in microfuge tubes containing sodium citrate (3.4 % w/v) 
as an anticoagulant. To separate the plasma, sample were 
centrifuged for 10 min at 3,500 rpm at 4 °C temperature. 
The method reported by Punna Rao et al. was used for 
analysis of drug plasma samples after suitable partial 
validation in rabbit plasma (Punna Rao et al., 2015).
• Statistical analyses
Unpaired Student’s t-test at 95% CI was used 
to determine the significance in difference of mean 
viscosities as a function of gellan gum and sodium citrate 
concentrations. In the in-vitro drug release studies, we used 
linear regression analysis to identify the best-fit model 
to describe the drug release kinetics from the optimized 
formulation. In the in-vivo studies, unpaired Student’s 
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t-test at 90% CI was used to assess the difference between 
the pharmacokinetic paramters (Cmax, Tmax and AUC) 
obtained after dosing marketed and test formulations. 
 
RESULTS AND DISCUSSION
Determination of gelation time
It was found that formulations F1 to F4 did not 
form a gel and remained in a honey-like consistency. 
Hence, these formulations were not considered for further 
studies. Formulations F5 and F6 formed spoon thick gel 
within 30 minutes of preparation and formulation F7 to 
F10 formed gel immediately at the end of the preparation. 
Data shown in Table II. 
Appearance and texture evaluation
All the formulated gels were translucent in 
appearance. As shown in Table II, formulations F1 to F6 
were non-sticky and non-gritty. Formulations F7 and F8 
were slightly sticky and non-gritty. Formulations F9 and 
F10 were sticky and slightly gritty in nature as determined 
visually and by mildly rubbing between two fingers. 
Stickiness of gel formulations increased with increase in 
concentration of the polymer. 
pH of the gel and syneresis
pH and syneresis are interconnected to each other 
(Setouhy, Malak, 2010). pH has an influence on syneresis. 
Hence, adjustment of pH plays an important role in 
preventing syneresis (Dixit, Parthasarathi, Hosakote, 
2011). Moreover, pH also has an influence on taste of the 
final formulation. Syneresis is one of the major problems 
associated with gels where very low concentration of 
gelling agent is used. Formulations F7 to F10 did not show 
any signs of syneresis during storage between 4-8 ᴼC in 
refrigerator for 90 days. Hence, these gel formulations 
were selected for further studies. Slight syneresis was 
observed in formulations F5 and F6. This could be due 
to low polymer concentration in the formulation. Hence, 
these formulations were not considered for further studies. 
Data are shown in Table II.
FTIR
FTIR studies were performed on pure drug and 
physical mixture of the gel formulation. All characteristic 
peaks of NEB were present in their original positions, 
denoting the absence of drug-excipient interaction. FTIR 
spectrum of NEB shows characteristic peaks at 3195 cm-1 
(O-H stretching), 2982, 2921, 2848 cm-1 (C-H stretching), 
and 1621, 1544 cm-1(C=C stretching), 1302 cm-1 (C-N 
stretching) and 1139 cm-1(C-O stretching). IR spectra are 
shown in Fig. 1. From the figure, no shifts in peak positions 
were observed for pure NEB (Fig. 1. A), in physical 
mixture of the gel formulation (Fig. 1. B).
DSC
DSC curve (Fig.2 A) shows a sharp endotherm at 
228° C that corresponds to NEB. However, as seen in 
Fig.2 B, the NEB peak is absent. Apparently, the drug is 
in a dissolved/amorphous state within the gel matrix. Peak 
at 72 °C in Fig.2 B, corresponds to that of gellan gum.
Viscosity and consistency
Normally, the process of oral swallowing happens 
at a shear rate of ~50/s at 25°C. Perceptual viscosity 
discrimination studies have been used to estimate the 
TABLE II - Evaluation of edible gel formulations
SL.No Evaluation parameters
Formulations
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10
1 Gelation time (min) + + + + 30 30 ++ ++ ++ ++
2 pH of gel 5.63 5.68 5.58 5.67 5.70 5.75 5.78 5.80 5.68 5.73
3 Syneresis - - - - No No No No No No
4 Texture NS, NG NS, NG NS, NG NS, NG NS, NG NS, NG SS, NG SS, NG S, SG S, SG
5 Viscosity (cps) 512 837 1563 1835 2776 3826 5107 7854 8948 9685




















*NS- Non Sticky, NG- Non Gritty, SS- Slightly Sticky, S – Sticky, SG- Slightly Gritty ‘+‘indicates complete gel has not been 
formed and consistency remained honey like, ‘++’ indicates gel has formed immediately at the end of the preparation.
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FIGURE 1 - IR-spectrum of pure nebivolol (A); IR-spectrum of Physical mixture of OEG formulation (B). Scans were performed 
from 400-4000cm-1. Average of 40 scans was taken. 
FIGURE 2 - DSC curve of pure nebivolol (A); optimized OEG formulation (B).
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lingual shear rates (Germain, Dufresne, Ramaswamy, 
2006). However, there is little, or no consensus between 
different studies with the values ranging from 5 to 1000/s 
(Germain, Dufresne, Ramaswamy, 2006). Nevertheless, 
the shear rate value of 50/s is widely accepted for 
estimation purposes (Steele, Van Lieshout, Goff, 2003).
In our studies, all the samples were found to be 
shear thinning in behavior as they exhibited a reduction 
in viscosity with increasing shear rate. We studied the 
effect of sodium citrate concentration on viscosity of gels 
formed with increasing amount of polymer. Data is shown 
in Table II. As one may expect, there was linear increase in 
viscosity with increasing polymer concentration. However, 
when we compared viscosities of different formulations, 
there was a significant (p < 0.05) difference between 
viscosities of gels formed with 0.4 % w/v and 0.5% 
w/v gellan gum when different concentration of sodium 
citrate (0.3 and 0.5% w/v) were used. Data depicted in 
Figure 3.
Apparently, sodium citrate provides cations that 
cause inter and intra cross linking of gellan gum’s 
polymeric chains leading to an increase in viscosity (Gohel 
et al., 2009). This was not very evident at lower polymer 
concentration because apparently the amount of cations 
provided by sodium citrate is in far excess. At higher 
polymer concentration, with increase in sodium citrate 
levels, more inter chain cross linking occurs leading to a 
significant increase in viscosity. 
Drug content assay
The drug content was determined using HPLC after 
appropriate dilution (Sahoo, Giri, 2009). Experiment was 
performed in triplicate. The assay was within 95-105% of 
the label claim in all the tested formulations. 
In vitro drug release studies and release kinetics
All the in vitro drug release studies were done 
in triplicate (n = 3). The optimized drug formulation 
showed over 95% drug release in 20 min (Figure 4). The 
drug release followed first order release kinetics. The 
Table III provides various parameters after fitting the drug 
release data of optimized formulation (F7) into different 
mathematical models. Based on the least square regression 
equation and obtained r2 values, the best-fit model was 
found to be first order model (r2 = 0.996).
Stability
The optimized edible gel formulations were stored at 
25 °C ± 0.2 °C/60 ± 5% RH and 40 °C ± 0.2 °C/75 ± 5% RH 
in a stability chamber (Ostwald stability chamber JRIC-11) 
for a period of 6 and 3 months respectively. It was observed 
that, gels stored at 40 °C/75% RH became physically 
unstable. Syneresis was observed in this condition. 
However, no physical/chemical changes were evident in 
the formulation at 25 °C/60% RH. The data presented in 
Figure 5.
In vivo studies
Formulation F7 was optimized as it showed 95% 
drug release in 20 min and was free from syneresis and 
grittiness. Formulations F1-F4 did not form gel while, F5-
F6 took a longer time to form gel. Formulations, F8-F10 
formed viscous gels and showed a retarded drug release as 
compared to F7. Considering these factors, formulation F7 
was optimized and selected for in-vivo pharmacokinetic 
studies in male New Zealand white rabbits (n = 6, 
n = 3 for each formulation). The time vs plasma drug 
concentration data obtained from pharmacokinetic studies 
are presented in Figure 6. Unpaired Student t-test was used 
to compare the significance between means of two groups 
at 90% confidence interval. From the figure, it is evident 
that, compared to marketed formulations, there was a 
significant difference (p < 0.1) in Tmax and Cmax values of 
FIGURE 3 - Effect of sodium citrate concentration (0.3 % and 
0.5% w/v) on viscosity of OEG formulations with increasing 
gellan gum concentration (0.1 % to 0.5% w/v).
TABLE III - Model fitting of optimized (F7) formulation
Model r2 n
Zero Order 0.404 -
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the gel formulation. Early Tmax was achieved (45 min) in 
the gel formulation. 
The method reported by Punna Rao et al. was used 
for analysis of drug plasma samples after suitable partial 
validation in rabbit plasma (Punna Rao et al., 2015). No 
interfering peaks were seen at the drug’s RT in the rabbit 
plasma matrix. A representative chromatogram for the 
same is shown in Figure 7.
Higher Cmax and earlier Tmax was achieved in case of 
the gel formulation compared to conventional marketed 
product. This was attributed to a higher rate of dissolution, 
better solubility and by pass of the first pass metabolism 
(Ketan, Anuradha, Jignasa, 2012). This was further 
confirmed by comparing AUC0-t of the formulations. 
Design of edible gel formulation can bypass first pass effect 
because some percentage of drug gets absorbed through 
buccal cavity, thus avoiding first pass effect. Compared to 
marketed formulation, the gel formulation showed similar 
AUC0-t profiles (Frel = 102%). Nevertheless, the authors wish 
to draw the attention of the reader to the fact that in these 
studies, the number of animals used in the experiments were 
small (n = 3 in each group). Therefore, though the results of 
this study appear promising, it would be prudent to validate 
the results in a larger group of animals across different 
species before extrapolating the same to humans. The 
pharmacokinetic parameters are summarized in Table IV. 
FIGURE 4 - In vitro drug release profile in pH 6.8 buffer for OEG formulations F5-F7 (A) and F8-F10 (B). 
FIGURE 5 - Stability data of the optimized OEG formulation. 
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FIGURE 6 - Plasma concentration–time profile of nebivolol in New Zealand white rabbits followed by oral administration of 
marketed immediate release tablets and optimized OEG formulation (10 mg/kg, n = 3).
FIGURE 7 - Overlaid HPLC chromatograms of blank plasma matrix (A), externally spiked plasma sample (250 ng/mL) (B) and 
sample from actual pharmacokinetic study (C). Drug peak at 7.6 min RT is from the analyte nebivolol.
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CONCLUSION
In this study, we have made systematic efforts to 
prepare edible gel formulation of NEB by using gellan 
gum. Edible gel formulation could significantly reduce the 
time taken to reach peak plasma concentration (Tmax) and 
maximum plasma concentration (Cmax) with comparable 
bioavailability. Based on these preliminary studies, the 
gel formulation appears better than the conventional 
tablets for dysphasic patients. However, thorough clinical 
investigation is necessary before extrapolating the results 
to humans. 
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